文献速递烧伤创面修复瘢痕与激光

局部外用重组人促红细胞生成素对烧伤创面愈合的潜在治疗效果:一项初步随机双盲对照临床试验

Potential therapeutic effects of topical recombinant human erythropoietin on burn wound healing: A preliminary randomized double-blind controlled clinical trial.
PubMed 文献 · Burns · 2024-09-17

这项随机双盲对照临床试验纳入40例烧伤后24小时内就诊的18岁及以上患者,比较局部外用重组人促红细胞生成素(rhEPO)与呋喃西林/维生素A对烧伤创面愈合的效果。结果显示,在第二次随访时,除瘙痒外,rhEPO组所有参数均显著低于对照组;第5、7、14天改良温哥华瘢痕量表(VSS)总分在rhEPO组显著低于常规护理组。作者认为局部外用rhEPO是烧伤创面的一种潜在选择,且患者满意度较好,无不可耐受副作用。

要点

  • 局部外用rhEPO组在第二次随访时除瘙痒外所有参数均显著低于对照组。
  • 第5、7、14天改良VSS总分在rhEPO组显著低于常规护理组。
  • 作者认为局部外用rhEPO是烧伤创面的潜在选择,患者满意度较好,无不可耐受副作用。

核心结论

  • 作者认为局部外用rhEPO是烧伤创面的一种潜在选择,且患者满意度较好,无不可耐受副作用。

研究设计与样本

  • 随机双盲对照临床试验,纳入40例18岁及以上、烧伤后24小时内转诊至烧伤中心的参与者。
  • 参与者无并发疾病,为浅度和深度二度烧伤,无呼吸道烧伤、无面部和会阴部烧伤、无瘢痕疙瘩形成,或为已愈合、完全上皮化的增生性烧伤瘢痕。
  • 局部外用rhEPO或呋喃西林/维生素A隔日给药,患者按计划随访接受创面清洁、清创和换药。

主要发现

  • 在第二次随访时,除瘙痒外,rhEPO组所有参数均显著低于对照组。
  • 接下来两次随访的结果也相同。
  • 第5、7、14天改良温哥华瘢痕量表(VSS)总分在rhEPO组显著低于常规护理组。

临床怎么用

  • 作者认为局部外用rhEPO是烧伤创面的潜在选择,且患者满意度较好,无不可耐受副作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Burn injuries can cause significant mortality and morbidity. This study aimed to evaluate the efficiency of topical recombinant human erythropoietin (rhEPO) on enhancing burn wound healing. METHODS: In this randomized double-blind controlled clinical trial, we enrolled 40 participants aged 18 years and older who were referred to a burn center during the first 24 h of burning. The participants with no concurrent comorbidities had superficial and deep second-degree burns, no respiratory burns, no face and perineum burns, no keloid formation, or a healed, fully epithelialized, hypertrophic burn scar. Topical rhEPO or nitrofurazone/Vitamin A was administered every other day, and the patients were scheduled for follow-up visits to receive wound cleansing, debridement, and dressing changes. Burn wound healing response to treatment was measured as the study main outcome. RESULTS: At the second follow-up visit, all parameters were significantly lower in the rhEPO group compared with the control group except for itchiness. The results of the next two follow-up sessions were also the same. The total value of the modified Vancouver Scar Scale (VSS) at days 5, 7, and 14 was significantly lower in the rhEPO group compared with the routine of care group. Trial Registry Date: 2022-03-02, Trial Registry number: IRCT20190810044500N23 CONCLUSIONS: The results of the present study suggested that topical rhEPO is a potential option in burn wounds and patient satisfaction, without causing intolerable side effects.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Saghafi F, Mohammadi F, Hoseinzade F, et al. Potential therapeutic effects of topical recombinant human erythropoietin on burn wound healing: A preliminary randomized double-blind controlled clinical trial. Burns. 2024. PMID: 39343631. doi:10.1016/j.burns.2024.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。